Pilot Study: Evaluation of Dual-Energy Computed Tomography Measurement Strategies for Positron Emission Tomography Correlation in Pancreatic Adenocarcinoma

Jorge Oldan, Miao He, Teresa Wu, Alvin C. Silva, Jing Li, J. Ross Mitchell, William M. Pavlicek, Michael C. Roarke, Amy K. Hara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We sought to determine whether dual-energy computed tomography (DECT) measurements correlate with positron emission tomography (PET) standardized uptake values (SUVs) in pancreatic adenocarcinoma, and to determine the optimal DECT imaging variables and modeling strategy to produce the highest correlation with maximum SUV (SUVmax). We reviewed 25 patients with unresectable pancreatic adenocarcinoma seen at Mayo Clinic, Scottsdale, Arizona, who had PET–computed tomography (PET/CT) and enhanced DECT performed the same week between March 25, 2010 and December 9, 2011. For each examination, DECT measurements were taken using one of three methods: (1) average values of three tumor regions of interest (ROIs) (method 1); (2) one ROI in the area of highest subjective DECT enhancement (method 2); and (3) one ROI in the area corresponding to PET SUVmax (method 3). There were 133 DECT variables using method 1, and 89 using the other methods. Univariate and multivariate analysis regression models were used to identify important correlations between DECT variables and PET SUVmax. Both R2 and adjusted R2 were calculated for the multivariate model to compensate for the increased number of predictors. The average SUVmax was 5 (range, 1.8–12.0). Multivariate analysis of DECT imaging variables outperformed univariate analysis (r = 0.91; R2 = 0.82; adjusted R2 = 0.75 vs r < 0.58; adjusted R2 < 0.34). Method 3 had the highest correlation with PET SUVmax (R2 = 0.82), followed by method 1 (R2 = 0.79) and method 2 (R2 = 0.57). DECT thus has clinical potential as a surrogate for, or as a complement to, PET in patients with pancreatic adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)824-832
Number of pages9
JournalJournal of Digital Imaging
Volume27
Issue number6
DOIs
StatePublished - Nov 6 2014

Fingerprint

Positron emission tomography
Positron-Emission Tomography
Tomography
Adenocarcinoma
Multivariate Analysis
Imaging techniques
Tumors

Keywords

  • Cancer
  • Dual-energy CT
  • Informatics
  • Pancreas
  • Pancreatic adenocarcinoma
  • PET
  • PET/CT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Computer Science Applications

Cite this

Pilot Study : Evaluation of Dual-Energy Computed Tomography Measurement Strategies for Positron Emission Tomography Correlation in Pancreatic Adenocarcinoma. / Oldan, Jorge; He, Miao; Wu, Teresa; Silva, Alvin C.; Li, Jing; Mitchell, J. Ross; Pavlicek, William M.; Roarke, Michael C.; Hara, Amy K.

In: Journal of Digital Imaging, Vol. 27, No. 6, 06.11.2014, p. 824-832.

Research output: Contribution to journalArticle

Oldan, Jorge ; He, Miao ; Wu, Teresa ; Silva, Alvin C. ; Li, Jing ; Mitchell, J. Ross ; Pavlicek, William M. ; Roarke, Michael C. ; Hara, Amy K. / Pilot Study : Evaluation of Dual-Energy Computed Tomography Measurement Strategies for Positron Emission Tomography Correlation in Pancreatic Adenocarcinoma. In: Journal of Digital Imaging. 2014 ; Vol. 27, No. 6. pp. 824-832.
@article{804bb8da3d514c4cb17bfae74c31e1d4,
title = "Pilot Study: Evaluation of Dual-Energy Computed Tomography Measurement Strategies for Positron Emission Tomography Correlation in Pancreatic Adenocarcinoma",
abstract = "We sought to determine whether dual-energy computed tomography (DECT) measurements correlate with positron emission tomography (PET) standardized uptake values (SUVs) in pancreatic adenocarcinoma, and to determine the optimal DECT imaging variables and modeling strategy to produce the highest correlation with maximum SUV (SUVmax). We reviewed 25 patients with unresectable pancreatic adenocarcinoma seen at Mayo Clinic, Scottsdale, Arizona, who had PET–computed tomography (PET/CT) and enhanced DECT performed the same week between March 25, 2010 and December 9, 2011. For each examination, DECT measurements were taken using one of three methods: (1) average values of three tumor regions of interest (ROIs) (method 1); (2) one ROI in the area of highest subjective DECT enhancement (method 2); and (3) one ROI in the area corresponding to PET SUVmax (method 3). There were 133 DECT variables using method 1, and 89 using the other methods. Univariate and multivariate analysis regression models were used to identify important correlations between DECT variables and PET SUVmax. Both R2 and adjusted R2 were calculated for the multivariate model to compensate for the increased number of predictors. The average SUVmax was 5 (range, 1.8–12.0). Multivariate analysis of DECT imaging variables outperformed univariate analysis (r = 0.91; R2 = 0.82; adjusted R2 = 0.75 vs r < 0.58; adjusted R2 < 0.34). Method 3 had the highest correlation with PET SUVmax (R2 = 0.82), followed by method 1 (R2 = 0.79) and method 2 (R2 = 0.57). DECT thus has clinical potential as a surrogate for, or as a complement to, PET in patients with pancreatic adenocarcinoma.",
keywords = "Cancer, Dual-energy CT, Informatics, Pancreas, Pancreatic adenocarcinoma, PET, PET/CT",
author = "Jorge Oldan and Miao He and Teresa Wu and Silva, {Alvin C.} and Jing Li and Mitchell, {J. Ross} and Pavlicek, {William M.} and Roarke, {Michael C.} and Hara, {Amy K.}",
year = "2014",
month = "11",
day = "6",
doi = "10.1007/s10278-014-9707-y",
language = "English (US)",
volume = "27",
pages = "824--832",
journal = "Journal of Digital Imaging",
issn = "0897-1889",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Pilot Study

T2 - Evaluation of Dual-Energy Computed Tomography Measurement Strategies for Positron Emission Tomography Correlation in Pancreatic Adenocarcinoma

AU - Oldan, Jorge

AU - He, Miao

AU - Wu, Teresa

AU - Silva, Alvin C.

AU - Li, Jing

AU - Mitchell, J. Ross

AU - Pavlicek, William M.

AU - Roarke, Michael C.

AU - Hara, Amy K.

PY - 2014/11/6

Y1 - 2014/11/6

N2 - We sought to determine whether dual-energy computed tomography (DECT) measurements correlate with positron emission tomography (PET) standardized uptake values (SUVs) in pancreatic adenocarcinoma, and to determine the optimal DECT imaging variables and modeling strategy to produce the highest correlation with maximum SUV (SUVmax). We reviewed 25 patients with unresectable pancreatic adenocarcinoma seen at Mayo Clinic, Scottsdale, Arizona, who had PET–computed tomography (PET/CT) and enhanced DECT performed the same week between March 25, 2010 and December 9, 2011. For each examination, DECT measurements were taken using one of three methods: (1) average values of three tumor regions of interest (ROIs) (method 1); (2) one ROI in the area of highest subjective DECT enhancement (method 2); and (3) one ROI in the area corresponding to PET SUVmax (method 3). There were 133 DECT variables using method 1, and 89 using the other methods. Univariate and multivariate analysis regression models were used to identify important correlations between DECT variables and PET SUVmax. Both R2 and adjusted R2 were calculated for the multivariate model to compensate for the increased number of predictors. The average SUVmax was 5 (range, 1.8–12.0). Multivariate analysis of DECT imaging variables outperformed univariate analysis (r = 0.91; R2 = 0.82; adjusted R2 = 0.75 vs r < 0.58; adjusted R2 < 0.34). Method 3 had the highest correlation with PET SUVmax (R2 = 0.82), followed by method 1 (R2 = 0.79) and method 2 (R2 = 0.57). DECT thus has clinical potential as a surrogate for, or as a complement to, PET in patients with pancreatic adenocarcinoma.

AB - We sought to determine whether dual-energy computed tomography (DECT) measurements correlate with positron emission tomography (PET) standardized uptake values (SUVs) in pancreatic adenocarcinoma, and to determine the optimal DECT imaging variables and modeling strategy to produce the highest correlation with maximum SUV (SUVmax). We reviewed 25 patients with unresectable pancreatic adenocarcinoma seen at Mayo Clinic, Scottsdale, Arizona, who had PET–computed tomography (PET/CT) and enhanced DECT performed the same week between March 25, 2010 and December 9, 2011. For each examination, DECT measurements were taken using one of three methods: (1) average values of three tumor regions of interest (ROIs) (method 1); (2) one ROI in the area of highest subjective DECT enhancement (method 2); and (3) one ROI in the area corresponding to PET SUVmax (method 3). There were 133 DECT variables using method 1, and 89 using the other methods. Univariate and multivariate analysis regression models were used to identify important correlations between DECT variables and PET SUVmax. Both R2 and adjusted R2 were calculated for the multivariate model to compensate for the increased number of predictors. The average SUVmax was 5 (range, 1.8–12.0). Multivariate analysis of DECT imaging variables outperformed univariate analysis (r = 0.91; R2 = 0.82; adjusted R2 = 0.75 vs r < 0.58; adjusted R2 < 0.34). Method 3 had the highest correlation with PET SUVmax (R2 = 0.82), followed by method 1 (R2 = 0.79) and method 2 (R2 = 0.57). DECT thus has clinical potential as a surrogate for, or as a complement to, PET in patients with pancreatic adenocarcinoma.

KW - Cancer

KW - Dual-energy CT

KW - Informatics

KW - Pancreas

KW - Pancreatic adenocarcinoma

KW - PET

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=84919575933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919575933&partnerID=8YFLogxK

U2 - 10.1007/s10278-014-9707-y

DO - 10.1007/s10278-014-9707-y

M3 - Article

C2 - 24994547

AN - SCOPUS:84919575933

VL - 27

SP - 824

EP - 832

JO - Journal of Digital Imaging

JF - Journal of Digital Imaging

SN - 0897-1889

IS - 6

ER -